Bedfordshire, Luton and Milton Keynes Area Prescribing Committee
Ref: APC Bulletin 295
Bulletin Date: 21/06/22
Review Date: March 2024
Lipid Management for Primary and Secondary Prevention of Cardiovascular Disease (CVD)
Updated Bulletin (March 2022)
Lipid management for Primary and Secondary prevention of CVD
To support the delivery of the NHS Long Term Plan, the Accelerated Access Collaborative (AAC) Lipid Management Rapid Uptake Product (RUP) Working Group has developed a NICE-endorsed clinical pathway for the management of lipids in primary and secondary prevention of CVD.
The pathway has been updated by the AAC to include Inclisiran▼ (Leqvio®) following the release of its positive NICE TA for treating primary hypercholesterolaemia or mixed dyslipidaemia.
The APC committee agreed to ratify the updated pathway and work on the local implementation of the pathway is ongoing.